“Serotonin pathway blockade in pulmonary arterial hypertension”, The Lancet Respiratory Medicine, September 19, 2024

Article exploring the serotonin pathway in pulmonary arterial hypertension care published in The Lancet Respiratory Medicine on September 19, 2024, titled “Serotonin pathway blockade in pulmonary arterial hypertension”. The author is Marcin Kurzyna, MD, PhD, FESC Citation Serotonin pathway blockade in pulmonary arterial hypertension, Kurzyna, Marcin, The Lancet Respiratory Medicine, Volume 0, Issue 0, DOI: 10.1016/S2213-2600(24)00291-1 […]

“Serotonin pathway blockade in pulmonary arterial hypertension”, The Lancet Respiratory Medicine, September 19, 2024 Read Post »

“Gaps in evidence in the treatment of prevalent patients with pulmonary arterial hypertension at intermediate risk: An expert consensus”, Vascular Pharmacology, September 10, 2024

Abstract “Despite the innovations introduced in the 2022 European Society of Cardiology/European Respiratory Society Guidelines on Pulmonary Hypertension, risk discrimination and management of pulmonary arterial hypertension patients at intermediate risk still represents a grey zone. Additionally, clinical evidence derived from currently available studies is limited. This expert panel survey intends to aid physicians in choosing

“Gaps in evidence in the treatment of prevalent patients with pulmonary arterial hypertension at intermediate risk: An expert consensus”, Vascular Pharmacology, September 10, 2024 Read Post »

Could artificial intelligence contribute to earlier diagnosis of pulmonary arterial hypertension? Recent research shows promising results, “Managed Healthcare Executive”, August 20, 2024

Over the past decade, significant strides have been made in diagnosing and treating pulmonary hypertension, driven by updated criteria and new medications. However, timely diagnosis remains a major challenge, with many patients facing long delays, often waiting years and consulting multiple doctors before receiving an accurate diagnosis. Journalist and healthcare writer Jared Kaltwasser has recently

Could artificial intelligence contribute to earlier diagnosis of pulmonary arterial hypertension? Recent research shows promising results, “Managed Healthcare Executive”, August 20, 2024 Read Post »

Recent study suggests that resistin could be a key biomarker and therapeutic target in pulmonary arterial hypertension, “Respiratory Research”, June 6, 2024

The findings of study which aimed to evaluate the potential for using resistin as a genetic and biological marker for disease severity and survival in pulmonary arterial hypertension were published on June 6, 2024 in “Pulmonary Research”. Resistin is an adipose-derived hormone (similar to a cytokine). The researchers collected biospecimens, clinical, and genetic data for 1.121 adults

Recent study suggests that resistin could be a key biomarker and therapeutic target in pulmonary arterial hypertension, “Respiratory Research”, June 6, 2024 Read Post »

Practical management of oral treprostinil in patients with pulmonary arterial hypertension: Lessons from ADAPT, EXPEDITE, and expert consensus, “Respiratory Medicine”

Oral treprostinil is a prostacyclin analogue approved to treat pulmonary arterial hypertension (PAH). A study analysing the practical management of oral treprostinil in patients with pulmonary arterial hypertension has been published on “Respiratory Medicine” Volume 231, 107734, September 2024. The article is based on results of the ADAPT and EXPEDITE trials and expert consensus. The

Practical management of oral treprostinil in patients with pulmonary arterial hypertension: Lessons from ADAPT, EXPEDITE, and expert consensus, “Respiratory Medicine” Read Post »

Aerovate Therapeutics announces that its pulmonary arterial hypertension candidate AV-101 failed to meet its primary endpoint in the Phase IIb portion of the IMPAHCT trial

Aerovate Therapeutics has announced that its pulmonary arterial hypertension (PAH) candidate AV-101 failed to meet its primary endpoint in the Phase IIb portion of the IMPAHCT trial. The Phase IIb portion of the IMPAHCT trial aimed to assess three different doses of AV-101, a novel dry powder inhaled formulation of imatinib. The primary endpoint tested

Aerovate Therapeutics announces that its pulmonary arterial hypertension candidate AV-101 failed to meet its primary endpoint in the Phase IIb portion of the IMPAHCT trial Read Post »

Interesting analysis of the prognostic value of the “Multicomponent Improvement” (MCI) endpoint in patients with pulmonary arterial hypertension (PAH) treated with sotatercept

The Multicomponent Improvement” (MCI) endpoint is a composite endpoint measuring improvement in 6-minute walk distance, reduction or maintenance of low N-terminal pro-BNP levels, and improvement or maintenance of WHO functional class I or II. The American Journal of Respiratory and Critical Care Medicine has published the abstract of a session at the American Thoracic Society

Interesting analysis of the prognostic value of the “Multicomponent Improvement” (MCI) endpoint in patients with pulmonary arterial hypertension (PAH) treated with sotatercept Read Post »

“Fundamentals of Genetic Testing”, a live webinar organised by the Pulmonary Hypertension Association (PHA) in collaboration with with partners TBX4life and Fundación Contra la Hipertensión Pulmonar, June 11, 2024

The Pulmonary Hypertension Association (PHA) is holding a webinar of “Fundamentals of Genetic Testing“ on Tuesday, June 11, at 2 p.m. EDT/ 6 p.m. UTC in collaboration with TBX4Life and Fundación Contra la Hipertensión Pulmonar Featured topics include The webinar will be available in English and Spanish. Speakers Harm Jan Bogaard, MD, PhDProfessor of Experimental Pulmonary MedicinePulmonologist, Department

“Fundamentals of Genetic Testing”, a live webinar organised by the Pulmonary Hypertension Association (PHA) in collaboration with with partners TBX4life and Fundación Contra la Hipertensión Pulmonar, June 11, 2024 Read Post »

Can dietary changes treat pulmonary hypertension? A new study suggests that some foods may affect blood vessel stiffening in pulmonary hypertension

The Cell metabolism journal has published a study by the University of Pittsburgh researcher Stephen Chan, MD, PhD, and colleagues from the team of Thomas Bertero at the Université Côte d’Azur in France, which explores the relation between diet and pulmonary hypertension. The findings reveal that hypertensive pulmonary blood vessel cells have an “appetite” for two

Can dietary changes treat pulmonary hypertension? A new study suggests that some foods may affect blood vessel stiffening in pulmonary hypertension Read Post »

A groundbreaking medical innovation known as the “sentinel skin flap” may hold the key to early detection of rejection in lung transplant patients

Could a medical innovation known as the “sentinel skin flap” hold the key to early detection of rejection in lung transplant patients? This pioneering technique, currently under investigation in a trial conducted by the University of Oxford and NHS Blood and Transplant, offers new hope for enhancing post-transplant care. Leading the charge in this groundbreaking trial is Henk Giele,

A groundbreaking medical innovation known as the “sentinel skin flap” may hold the key to early detection of rejection in lung transplant patients Read Post »

United Therapeutics has been granted a patent for a method to treat pulmonary arterial hypertension (PAH) by administering endothelial progenitor cells treated with prostacyclin

United Therapeutics has been granted a patent for a method to treat pulmonary arterial hypertension (PAH) by administering endothelial progenitor cells treated with prostacyclin Application n° US17072430, December 12, 2023, Publication Number: US11839631B2. The news was reported in the Magazine “Pharmaceutical Technology, April 4, 2024. To be followed! Read more at this link on the

United Therapeutics has been granted a patent for a method to treat pulmonary arterial hypertension (PAH) by administering endothelial progenitor cells treated with prostacyclin Read Post »

Gas-filled balloon implanted in main pulmonary artery to alleviate right ventricle workload tested in pulmonary hypertension

The Aria CV Pulmonary Hypertension System is an implantable gas-filled balloon that is introduced percutaneously in the main pulmonary artery to alleviate the excessive workload on the right heart that results in right heart failure. An article published in the European Journal of Heart Failure on March 13, 2024 titled “Efficacy and safety of the

Gas-filled balloon implanted in main pulmonary artery to alleviate right ventricle workload tested in pulmonary hypertension Read Post »

Prof. Adam Torbicki explores access to care, Prof. Jean-Luc Vachiéry delves into drug development – watch the highlights from the PHA Europe Annual Conference online

Prof. Adam Torbicki’s presentation is titled “Access to care for pulmonary arterial hypertension and chronic thromboembolic pulmponary hypertension”. It can be viewed at this link on Vimeo (you need to register on Vimeo to see it) Prof. Jean-Luc Vachiéry’s presentation is titled “Drug development and clinical trials“. It can be viewed at this link on

Prof. Adam Torbicki explores access to care, Prof. Jean-Luc Vachiéry delves into drug development – watch the highlights from the PHA Europe Annual Conference online Read Post »

Prof. Frances de Man has been awarded a grant from the Dutch Heart Foundation for her research on the prevention of right heart failure in pulmonary hypertension

The Dutch Heart Foundation has awarded an “Established Investigator” grant to Prof. Dr. Frances de Man from the Amsterdam UMC. She is conducting research to better understand and prevent right heart failure in pulmonary hypertension. When the blood pressure in the lungs is too high (in pulmonary hypertension), the right ventricle has to work harder

Prof. Frances de Man has been awarded a grant from the Dutch Heart Foundation for her research on the prevention of right heart failure in pulmonary hypertension Read Post »

Wrapping up a successful year of pulmonary hypertension knowledge-sharing educational live web events!

The Alliance for Pulmonary Hypertension has just held the last webinar of the six-part series it launched in June 2023 exploring the innovations outlined in the 2022 joint clinical guidelines on pulmonary hypertension by the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Across these six insightful sessions, we delved into pivotal

Wrapping up a successful year of pulmonary hypertension knowledge-sharing educational live web events! Read Post »

“Patient partnership in cardiovascular clinical trials”, European Heart Journal

This paper, titled “”Patient partnership in cardiovascular clinical trials”, published in the European Heart Journal, assesses current initiatives and identifies opportunities for furthering meaningful patient involvement in cardiovascular clinical research. According to the authors, patients are fundamentally the ultimate beneficiaries of medical treatments, and their active engagement as contributors and decision-makers in the product development

“Patient partnership in cardiovascular clinical trials”, European Heart Journal Read Post »

Want to find out more about Medicines R & D and Patient Engagement? Check out the EUPATI Toolbox, now available in 14 languages!

“EUPATI” stands for European Patient Academy on Therapeutic Innovation. Its mission is to provide accessible, innovative and inclusive education that empowers patients and patient representatives with the right knowledge, skills and competencies to effectively engage and partner with all other stakeholders in medicines R&D. The EUPATI Toolbox is organised in two main areas: Medicines R&D

Want to find out more about Medicines R & D and Patient Engagement? Check out the EUPATI Toolbox, now available in 14 languages! Read Post »

The 2023 PHA Canada Research scholarship application process opens September 1, 2023!

PHA Canada’s scholarship program awards up to $10,000 to outstanding trainees in support of their research into the field of pulmonary hypertension. This research program allows emerging pulmonary hypertension researchers—whose projects will contribute to the better understanding or treatment of pulmonary hypertension—to fully delve into their scientific studies, in collaboration with specialized pulmonary hypertension clinics

The 2023 PHA Canada Research scholarship application process opens September 1, 2023! Read Post »

The fascinating story about how the first ever right heart catheterisation was performed by a German physician, Dr. Werner Forssman, on himself!

Right Heart Catheterization (RHC) is the gold standard for diagnosing and classifying pulmonary hypertension. The story behind its invention is captivating, highlighting the remarkable strides that individuals driven by a passion for science and innovation can take, often braving risks to their own well-being and even lives! Werner Forssmann was born in Berlin in 1904,

The fascinating story about how the first ever right heart catheterisation was performed by a German physician, Dr. Werner Forssman, on himself! Read Post »

TRANSLATE »
Scroll to Top